Articles from Bluejay Diagnostics

ACTON, MA / ACCESS Newswire / October 30, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 3, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 3, 2026 under the Company's existing trading symbol, "BJDX." At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633707.

Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site

SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission